Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) EBT Margin (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed EBT Margin for 15 consecutive years, with 12.74% as the latest value for Q4 2025.

  • Quarterly EBT Margin rose 1996.0% to 12.74% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 10.84% through Dec 2025, up 1446.0% year-over-year, with the annual reading at 10.84% for FY2025, 1446.0% up from the prior year.
  • EBT Margin hit 12.74% in Q4 2025 for Ani Pharmaceuticals, down from 14.84% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 18.43% in Q1 2024 to a low of 50.64% in Q4 2021.
  • Historically, EBT Margin has averaged 7.0% across 5 years, with a median of 0.47% in 2023.
  • Biggest five-year swings in EBT Margin: tumbled -4648bps in 2021 and later soared 4452bps in 2022.
  • Year by year, EBT Margin stood at 50.64% in 2021, then skyrocketed by 88bps to 6.12% in 2022, then soared by 112bps to 0.72% in 2023, then tumbled by -1104bps to 7.22% in 2024, then skyrocketed by 276bps to 12.74% in 2025.
  • Business Quant data shows EBT Margin for ANIP at 12.74% in Q4 2025, 14.84% in Q3 2025, and 4.98% in Q2 2025.